Dr. Lucie M. Turcotte

Claim this profile

University of Minnesota/Masonic Cancer Center

Studies Langerhans Cell Histiocytosis
Studies Cancer
4 reported clinical trials
7 drugs studied

Area of expertise

1Langerhans Cell Histiocytosis
Lucie M. Turcotte has run 2 trials for Langerhans Cell Histiocytosis.
2Cancer
Lucie M. Turcotte has run 2 trials for Cancer. Some of their research focus areas include:
Stage II
Stage I

Affiliated Hospitals

Image of trial facility.
University Of Minnesota/Masonic Cancer Center

Clinical Trials Lucie M. Turcotte is currently running

Image of trial facility.

DAY101

for Langerhans Cell Histiocytosis

This trial tests the safety and effectiveness of tovorafenib (DAY101) in children and young adults with Langerhans cell histiocytosis that is worsening, has returned, or does not respond to other treatments. Tovorafenib is taken orally and works by blocking enzymes needed for cancer cell growth. The study aims to find the best dose and observe the response and side effects over time.
Recruiting1 award Phase 228 criteria
Image of trial facility.

Vinblastine/Prednisone vs. Cytarabine

for Histiocytosis

Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body, where they can damage tissue or form lesions. For most patients with LCH, standard-of-care vinblastine/prednisone are used as front-line therapy while cytarabine therapy has been used as therapy for patients who develop recurrence. No alternate treatment strategy has been developed for frontline therapy in LCH. The purpose of this research study is to compare previously used vinblastine/prednisone to single therapy with cytarabine for LCH. We will evaluate the utility of an imaging study called a positron emission tomography (PET) scan to more accurately assess areas of LCH involvement not otherwise seen in other imaging studies as well as response to therapy. We also want to identify if genetic and other biomarkers (special proteins in patient's blood and in patient's cancer) relate to the response of patients LCH to study treatment.
Recruiting4 awards Phase 33 criteria

More about Lucie M. Turcotte

Clinical Trial Related8 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Lucie M. Turcotte has experience with
  • Cytarabine
  • Prednisone
  • Vinblastine
  • Multi-component Mobile Health And Social Media Physical Activity Intervention
  • Wearing A Physical Activity Tracker Alone
  • Web-Based Physical Activity Intervention

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Lucie M. Turcotte specialize in?
Is Lucie M. Turcotte currently recruiting for clinical trials?
Are there any treatments that Lucie M. Turcotte has studied deeply?
What is the best way to schedule an appointment with Lucie M. Turcotte?
What is the office address of Lucie M. Turcotte?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security